Liquid Biopsy Research Report 2025-2030 Including Executive, Consultant Guides and Customized Market Forecasting and Analysis - Next Generation Sequencing Fueling a Revolution
January 06, 2025 09:24 ET
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market By Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook, Including Executive, Consultant Guides and...
Clinical In Vitro Diagnostic Medical Laboratory Services Market Research 2025: Strategy, Trends, Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx
January 06, 2025 07:52 ET
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry,...
Breast Cancer Liquid Biopsy Market to hit USD 1.9 billion by 2032, says Global Market Insights Inc.
January 06, 2025 04:00 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Breast cancer liquid biopsy market size reached USD 305.9 million in 2023 and is projected to expand at a robust CAGR of 22.6% from 2024 to...
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
December 12, 2024 08:00 ET
|
Precede Biosciences, Inc.
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field todayThere are approximately...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
November 15, 2024 21:15 ET
|
Precede Biosciences, Inc.
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMABeyond Lutetium-PSMA, these results are...
Circulating Tumor Cells Patent Landscape and Forecast 2024-2032 - The U.S. Leads with Over 4,000 Patent Filings, Driven by Robust R&D Infrastructure and Substantial Investments in Cancer Diagnostics
November 12, 2024 08:11 ET
|
Research and Markets
Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Circulating Tumor Cells Patent Landscape Report and Forecast 2024-2032" has been added to ResearchAndMarkets.com's offering.The circulating tumor...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
September 19, 2024 10:50 ET
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
September 15, 2024 06:05 ET
|
Precede Biosciences, Inc.
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET...
Liquid Biopsy Market to Surpass USD 24.14 Billion by 2031, Witnessing 11.21% CAGR Growth | SkyQuest Technology
July 05, 2024 08:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, July 05, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the liquid biopsy market will attain a value of USD 24.14 billion by 2031, with a CAGR of 11.21% during the forecast period...
Global Experts to Convene for the Emerging Technologies for Diagnostics & Liquid Biopsies Conference 2024 in New Orleans (September 26-27th 2024)
June 26, 2024 04:01 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Emerging Technologies for Diagnostics & Liquid Biopsies - New Orleans 2024" conference has been added to ResearchAndMarkets.com's offering. The...